Is AARD or IXHL more profitable?

Aardvark Therapeutics' return on equity of -61.71% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -61.71% -56.29% Incannex Healthcare N/A -81.01% -76.11%

Is IXHL or CRDL more profitable?

Incannex Healthcare's return on equity of -81.01% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Cardiol Therapeutics N/A -229.43% -165.60%

Is NRXP or IXHL more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Incannex Healthcare N/A -81.01% -76.11%

Do analysts prefer IXHL or CUE?

Incannex Healthcare currently has a consensus price target of $18.00, indicating a potential upside of 512.24%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Incannex Healthcare (IXHL) Competitors

$2.94 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$2.90 -0.04 (-1.36%)

As of 07/31/2026 07:52 PM Eastern

Compare

IXHL vs. HUMA, AARD, CRDL, NRXP, and CUE

Should you buy Incannex Healthcare stock or one of its competitors? MarketBeat compares Incannex Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Incannex Healthcare include Humacyte (HUMA), Aardvark Therapeutics (AARD), Cardiol Therapeutics (CRDL), NRx Pharmaceuticals (NRXP), and Cue Biopharma (CUE).

How does Incannex Healthcare compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Humacyte has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	71.11	-$40.83M	-$0.57	N/A
Incannex Healthcare	$90K	391.02	-$46.88M	-$1.55	N/A

44.7% of Humacyte shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Incannex Healthcare has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Incannex Healthcare's return on equity of -81.01% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Incannex Healthcare	N/A	-81.01%	-76.11%

Humacyte has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.98, suggesting that its stock price is 598% more volatile than the broader market.

Humacyte currently has a consensus target price of $6.25, suggesting a potential upside of 856.54%. Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 512.24%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Humacyte had 5 more articles in the media than Incannex Healthcare. MarketBeat recorded 5 mentions for Humacyte and 0 mentions for Incannex Healthcare. Humacyte's average media sentiment score of 0.27 beat Incannex Healthcare's score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Neutral
Incannex Healthcare	Neutral

Summary

Humacyte beats Incannex Healthcare on 11 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Aardvark Therapeutics presently has a consensus price target of $16.30, suggesting a potential upside of 146.97%. Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 512.24%. Given Incannex Healthcare's higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aardvark Therapeutics' return on equity of -61.71% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Incannex Healthcare	N/A	-81.01%	-76.11%

In the previous week, Aardvark Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 2 mentions for Aardvark Therapeutics and 0 mentions for Incannex Healthcare. Aardvark Therapeutics' average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Incannex Healthcare	Neutral

Aardvark Therapeutics has a beta of 3.8, meaning that its stock price is 280% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.98, meaning that its stock price is 598% more volatile than the broader market.

Incannex Healthcare has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Incannex Healthcare	$90K	391.02	-$46.88M	-$1.55	N/A

0.4% of Incannex Healthcare shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Aardvark Therapeutics and Incannex Healthcare tied by winning 7 of the 14 factors compared between the two stocks.

How does Incannex Healthcare compare to Cardiol Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Incannex Healthcare's return on equity of -81.01% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cardiol Therapeutics has lower revenue, but higher earnings than Incannex Healthcare. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	391.02	-$46.88M	-$1.55	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

In the previous week, Cardiol Therapeutics had 10 more articles in the media than Incannex Healthcare. MarketBeat recorded 10 mentions for Cardiol Therapeutics and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.00 beat Cardiol Therapeutics' score of -0.07 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Cardiol Therapeutics	Neutral

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 512.24%. Cardiol Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 569.29%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Incannex Healthcare has a beta of 6.98, meaning that its share price is 598% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Summary

Cardiol Therapeutics beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.

How does Incannex Healthcare compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NRx Pharmaceuticals' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Incannex Healthcare	N/A	-81.01%	-76.11%

NRx Pharmaceuticals presently has a consensus price target of $38.25, suggesting a potential upside of 1,114.29%. Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 512.24%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NRx Pharmaceuticals has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.98, indicating that its stock price is 598% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals' average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Incannex Healthcare	Neutral

NRx Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	92.78	-$28.62M	-$1.09	N/A
Incannex Healthcare	$90K	391.02	-$46.88M	-$1.55	N/A

Summary

NRx Pharmaceuticals beats Incannex Healthcare on 9 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to Cue Biopharma?

Incannex Healthcare (NASDAQ:IXHL) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Incannex Healthcare has a beta of 6.98, meaning that its stock price is 598% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

In the previous week, Cue Biopharma had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 2 mentions for Cue Biopharma and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.00 equaled Cue Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Cue Biopharma	Neutral

Cue Biopharma has higher revenue and earnings than Incannex Healthcare. Cue Biopharma is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	391.02	-$46.88M	-$1.55	N/A
Cue Biopharma	$32.73M	3.44	-$26.60M	-$5.58	N/A

Incannex Healthcare currently has a consensus price target of $18.00, indicating a potential upside of 512.24%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Incannex Healthcare has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Incannex Healthcare's return on equity of -81.01% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Cue Biopharma	-59.65%	-98.30%	-53.69%

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Incannex Healthcare beats Cue Biopharma on 9 of the 15 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.19M	$11.72B	$6.85B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-1.90	799.05	282.28	24.66
Price / Sales	391.02	751.77	563.21	75.35
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	1.42	10.27	10.96	6.07
Net Income	-$46.88M	$2.82B	$3.49B	$347.99M
7 Day Performance	-1.34%	-0.18%	-0.63%	-0.44%
1 Month Performance	-25.94%	-4.02%	-5.23%	-4.81%
1 Year Performance	-74.58%	156.06%	62.07%	18.61%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	1.6664 of 5 stars	$2.94 flat	$18.00 +512.2%	-74.6%	$35.19M	$90K	N/A	3
HUMA Humacyte	3.5172 of 5 stars	$0.67 +7.9%	$6.25 +827.2%	-71.3%	$138.72M	$2.04M	N/A	150	Upcoming Earnings Analyst Upgrade Gap Up
AARD Aardvark Therapeutics	2.5866 of 5 stars	$6.69 +5.9%	$16.30 +143.6%	-45.6%	$138.31M	N/A	N/A	18
CRDL Cardiol Therapeutics	2.5583 of 5 stars	$1.16 -2.1%	$8.50 +635.9%	-8.0%	$135.99M	N/A	N/A	20	Positive News
NRXP NRx Pharmaceuticals	1.6639 of 5 stars	$3.63 -3.2%	$38.25 +953.7%	+21.6%	$135.86M	$1.23M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. HUMA, AARD, CRDL, NRXP, and CUE

How does Incannex Healthcare compare to Humacyte?

Summary

How does Incannex Healthcare compare to Aardvark Therapeutics?

Summary

How does Incannex Healthcare compare to Cardiol Therapeutics?

Summary

How does Incannex Healthcare compare to NRx Pharmaceuticals?

Summary

How does Incannex Healthcare compare to Cue Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. HUMA, AARD, CRDL, NRXP, and CUE

How does Incannex Healthcare compare to Humacyte?

Which has stronger earnings & valuation, HUMA or IXHL?

Do institutionals and insiders hold more shares of HUMA or IXHL?

Is HUMA or IXHL more profitable?

Which has more volatility and risk, HUMA or IXHL?

Do analysts recommend HUMA or IXHL?

Does the media prefer HUMA or IXHL?

Summary

How does Incannex Healthcare compare to Aardvark Therapeutics?

Do analysts recommend AARD or IXHL?

Is AARD or IXHL more profitable?

Does the media prefer AARD or IXHL?

Which has more volatility & risk, AARD or IXHL?

Which has better valuation & earnings, AARD or IXHL?

Do institutionals & insiders hold more shares of AARD or IXHL?

Summary

How does Incannex Healthcare compare to Cardiol Therapeutics?

Is IXHL or CRDL more profitable?

Do institutionals and insiders believe in IXHL or CRDL?

Which has higher earnings and valuation, IXHL or CRDL?

Does the media favor IXHL or CRDL?

Do analysts prefer IXHL or CRDL?

Which has more risk and volatility, IXHL or CRDL?

Summary

How does Incannex Healthcare compare to NRx Pharmaceuticals?

Do insiders and institutionals hold more shares of NRXP or IXHL?

Is NRXP or IXHL more profitable?

Do analysts rate NRXP or IXHL?

Which has more risk and volatility, NRXP or IXHL?

Does the media prefer NRXP or IXHL?

Which has preferable valuation & earnings, NRXP or IXHL?

Summary

How does Incannex Healthcare compare to Cue Biopharma?

Which has more risk and volatility, IXHL or CUE?

Does the media favor IXHL or CUE?

Which has better valuation and earnings, IXHL or CUE?

Do analysts prefer IXHL or CUE?

Is IXHL or CUE more profitable?

Do insiders & institutionals have more ownership in IXHL or CUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools